# Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

> **NCT07436858** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)
- HER2 Expression
- HER2 Gene Mutation

## Interventions

- **DIAGNOSTIC_TEST:** PET imaging with ⁸⁹Zr-trastuzumab
- **DIAGNOSTIC_TEST:** Blood sampling for pharmacokinetics

## Key facts

- **NCT ID:** NCT07436858
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2030-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07436858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07436858, "Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07436858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*